O’Melveny’s China Competition and Trade Reviews
offer periodic updates about important antitrust, competition, and
trade developments in China. The Reviews are intended to help
companies navigate China’s rapidly evolving regulatory
landscape with practical, on-the-ground insights into the
country’s competitive conditions and the laws framing
them.
This third installment offers a brief overview of:
- The impact of the novel coronavirus
(Covid-19) outbreak, which is upending business in China, slowing
M&A activity, and forcing the government to modify regulatory
procedures;
- Proposed revisions to China’s
Anti-Monopoly Law, which greatly increase penalties for
anticompetitive agreements and merger clearance violations, while
also increasing SAMR’s investigatory powers and clarifying a
number of important concepts in the law;